GlycoNex
Business Services · Taiwan · 51-200 Employees
View Company Info for Free
Overview
Headquarters
1 Xintai 5th Rd, Xizhi Dist., New Taipei...Phone Number
+886 226971168Website
www.glyconex.com.twRevenue
<$5 MillionIndustry
About GlycoNex
GlycoNex Org Chart
Is GlycoNex your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
GlycoNex, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when GlycoNex launches new products
Congratulate Masked Content for being promoted to Masked Content at GlycoNex
Check out if GlycoNex is spiking on competitors!
Click to see if GlycoNex had a recent Job posting/layoffs
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once GlycoNex has new funding data
Check if GlycoNex has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on GlycoNex recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined GlycoNex as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
GlycoNex is experiencing very low activity levels compared to other companies in the Business Services sector.
What does this means?
GlycoNex is drawing exceptional interest within the Business Services industry, suggesting notable developments or strong market momentum, learn more about GlycoNex.
GlycoNex Tech Stack
A closer look at the technologies used by GlycoNex
GlycoNex News & Media
GlycoNex Announces Positive Topline Results for Phase III Clinical Trial of Denosumab Biosimilar SPD8
NEW TAIPEI CITY, June 10, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), today announced that the Phase III clinical trial for SPD8, a Denosumab biosimilar co-developed with Mitsubishi Gas Chemical, has successfully met its primary endpoint. Statistical...GlycoNex Receives PMDA Approval in Japan to Initiate First-in-Human Phase 1 Trial of GNX1021 in Gastrointestinal Cancers
GNX1021 is a glycan-targeting antibody-drug conjugate designed to address tumor heterogeneity in gastrointestinal cancers NEW TAIPEI CITY, Taiwan, April 14, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), clinical stage biotechnology company focused on the...GlycoNex Inc. and Nippon Kayaku Co., Ltd. Enter Collaboration to Advance Next-Generation ADC Candidate GNX201-ADC
Partnership supports development of tumor-activated glycan-directed ADC designed to improve tumor selectivity NEW TAIPEI CITY, Taiwan, March 23, 2026 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a clinical-stage biotechnology company focused on the development of...GlycoNex Signs CDMO Service Agreement with Change Cure to Advance HMGB1-Targeted Antibody Program
Collaboration with Science Tokyo spinout underscores GlycoNex's integrated antibody development and manufacturing capabilities in support of first-in-class immunotherapies NEW TAIPEI CITY, Taiwan, Dec. 8, 2025 /PRNewswire/ -- GlycoNex, Inc. (4168, hereinafter referred to as GNX), a...
Top Business Services Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding GlycoNex
The transient expression system and antibody evaluation platform of GlycoNex have reached the highest standard; the company is able to precisely evaluate antibody candidates, accelerate drug development progress, lower the risk and elevate the screening efficiency. Holding "Professional, Dedication, Excellence" as the company's motto, GlycoNex will... Read More